Larry Todd Edwards - 27 Feb 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Reporting Person's title: EVP, Chief Commercial Officer
Issuer ticker: ARQT
Reported as of: 27 Feb 2026
Net transaction value: -$92,846
SEC form: 4
Accepted by SEC: 03 Mar 2026, 20:43:03 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards

Key filing fact

Larry Todd Edwards filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 03 Mar 2026.

Key facts

This page summarizes Larry Todd Edwards's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 20:43.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$92,846.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994805 Primary reporting owner

Edwards Larry Todd

Relationship: Reporting Person's title: EVP, Chief Commercial Officer
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %: +20%
Price: $0.000000
Shares after: 178,865
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

ARQT transaction

Common Stock

Sale

Transaction value: $90,177
Shares: -3,584
Change %: -2%
Price: $25.16
Shares after: 175,281
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F3

ARQT transaction

Common Stock

Sale

Transaction value: $2,669
Shares: -103
Change %: -0.06%
Price: $25.91
Shares after: 175,178
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +77,000
Change %
Price: $0.000000
Shares after: 77,000
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,000
Exercise price: $26.97
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

Footnote F3

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F5

1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

SEC remarks

Reporting Person's title: EVP, Chief Commercial Officer